Neuron Biopharma, S.A. filed its Annual on Apr 24, 2014 for the period ending Dec 31, 2013. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-.--% | -.--% |
2017 | Neuron BioLabs, S.L. cancelled the acquisition of diagnostics operations, R&D services and patents of Alzheimer's disease from Neuron Bio, SA. | CI |
2017 | Neol Biosolutions Seeks Investors | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 5.19M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.24% | 22.72B | |
-18.26% | 20.82B | |
-18.17% | 16.66B | |
-41.55% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- NEU Stock
- News Neuron Bio, S.A.
- Neuron Biopharma, S.A. Auditor Raises 'Going Concern' Doubt